The EMLc Subcommittee discussed the suggestion of adding cholecalciferol to ergocalciferol in appropriate, equivalent forms and dosages because of the better bioavailability and metabolic action of cholecalciferol. The Subcommittee agreed to endorse both cholecalciferol and ergocalciferol for listing in the EMLc for the treatment of vitamin D deficiencies. Ergocalciferol is noted as an alternative in the listing for cholecalciferol on the EMLc.